— Our Method / The Operating Mode
A two-layer growth operating model for healthcare, MedTech, and HealthTech companies at a commercial inflection point.
Strategy decides the target. Execution hits it.
— The Premise
Many growth-stage healthcare companies with credible science still stall, and not always for the reasons a board first suspects. Reimbursement, regulatory friction, clinical evidence, and health economics are real constraints. But some of the most expensive stalls are self-inflicted in a specific way: the company begins executing before it has decided what the market must understand, believe, and adopt.
It buys campaigns to fix a demand problem that is actually a positioning problem. It publishes content before it has a point of view worth citing. It optimizes for rankings while the buying committee it needs was never mapped. In healthcare, where clinical credibility and regulated buyers make generic playbooks fail, this sequence error is expensive and slow to detect.
The Bullzeye 3D Framework is built to prevent it. Layer One forces the strategic choices and will not let execution begin until each one clears a gate. Layer Two architects, tests, and scales against them.
— On the Name
3D is the lens, not the count. The framework applies three dimensions to strategy and the same three-dimensional discipline to execution. Layer One is Strategic 3D. Layer Two is Execution 3D. Two layers, one repeatable lens.
Naming the layers this way is deliberate: execution is not a department bolted on later, it is the same rigor applied to building what strategy chose.
— The Model at a Glance
| Strategic 3D | Differentiate | Disrupt | Dominate |
| Execution 3D | Design | Discover | Deploy |
— Layer One
Define the ideal customer, competitive position, category narrative, value proposition, and the specific problem the company should own.
Find where leaders are vulnerable, reframe the problem, build a proprietary point of view, and decide which buying criterion should favor the company.
Choose one advantage to compound until it is hard to displace: clinical credibility, proprietary data, authority, distribution, IP, switching costs, or category ownership.
— Layer Two
Execution hits the target. It does not build the full production system before the market has validated the strategy. It architects, tests, then scales.
Build a testable version of the system: information architecture, journey, SEO, AEO, and GEO structure, measurement plan, and the first assets needed to run real experiments. Not everything, yet.
Live, in-market validation: real audience and search behavior, experiments, message and conversion validation, AI-visibility measurement, and the citation and demand gaps. Learn before scaling.
Turn validated prototypes into the full production system: winning campaigns, the complete authority engine, distribution, repeatable operations, and the link from visibility to pipeline and revenue.
— How the Operating Model Runs
A company does not proceed until the gate is cleared. The strategic gates test that a choice is evidence-supported and testable, not that it has already won. Market recognition and citations are outcomes measured later, in Discover and Deploy. This is what makes it a growth operating model rather than a sequence of concepts.
| Dimension | Decision question | Required output | Gate to proceed |
|---|---|---|---|
| Differentiate | What can we credibly own that competitors cannot easily copy? | ICP and market, buyer and committee map, positioning, value proposition, reasons to believe | The market, buyer problem, and value claim are supported by customer evidence and competitive analysis |
| Disrupt | What market belief must change for us to win? | Proprietary point of view, category narrative, the buying criterion to be adopted | The point of view is specific, defensible, tied to a real tension, and capable of shifting a buying criterion |
| Dominate | Which advantage will we compound until it is hard to displace? | A chosen primary compounding mechanism with measurable ownership targets | The company has selected one advantage it can compound and defined how ownership is measured |
| Design | What system must exist to test the strategy? | Journey and architecture, prototype assets, SEO / AEO / GEO structure, measurement plan | A testable, instrumented version of the growth system is live |
| Discover | What has the market actually validated? | Experiment results, conversion data, AI-visibility measurement, gap analysis, decision record | In-market evidence shows which messages, assets, and channels deserve further investment |
| Deploy | What can scale profitably? | Production system, distribution build-out, operating cadence, pipeline-to-revenue linkage | A real commercial signal justifies scaling |
— Not a Waterfall
— How the Framework Applies
Healthcare commercialization. Clarify the market, reshape the buying decision, and build the systems that drive adoption.
AI visibility. Define the authority position, structure the knowledge architecture engines can retrieve, and measure citation and recommendation growth.
Executive growth strategy. Align leadership decisions, market narrative, and execution around commercial outcomes. This one runs across both layers rather than sitting in a single phase.
— The Systems Inside
None of these is a competing framework. Each has a distinct job inside the 3D operating model.
Governs decision quality across all six gates: what evidence to trust, and where a call must not be handed to AI or automation. Read more
The evidence engine. Supplies the market, buyer, competitive, and commercial intelligence the model runs on. Read more
The go-to-market playbook that turns clinical credibility into adoption and commercial movement.
The measurement spine that connects authority and demand signals to pipeline and revenue.
— Who It Is For
It is built for MedTech and HealthTech companies moving from early traction to real commercial scale, where the founder can no longer be the growth engine. It fits healthcare providers that need to grow volume without eroding clinical trust, and growth-stage B2B healthcare companies preparing for a raise or an exit, where investor readiness depends on a commercialization story that survives diligence.
It is not built for pre-product companies still searching for a clinical use case, or for teams that want execution without owning the strategic choices first. The model assumes you want a partner who sets the target with you, not a vendor who starts firing.
In practice. In advanced breast imaging, Bullzeye applied this model with Koning Health to reposition a clinically complex category, true 3D breast CT, into a digital experience built for both the clinician and the patient, moving from feature-led messaging toward a credibility-first structure aligned to how clinical buyers actually evaluate the category. Read the full case study
— Common Questions
Start Here